J&J, Medtronic back CereVasc Secures $85 Million in Latest Series C Funding Round

J&J, Medtronic back CereVasc secured $85 million in its latest Series C, adding another data point to the Digital Health funding market.

J&J, Medtronic back CereVasc Raises $85 million in Funding

J&J, Medtronic back CereVasc is a Digital Health company focused on advance its eShunt system for hydrocephalus treatment.

Investors Behind the Funding

The round was backed by Johnson & Johnson. Funding Intelligence tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

J&J, Medtronic back CereVasc operates in Digital Health. J&J, Medtronic back CereVasc's Series C round shows investors are still backing digital health platforms with real scale narratives. At $85M, the deal suggests buyers want category leaders that can turn AI, automation, or workflow leverage into durable enterprise demand.

Strategic Use of Funds

advance its eShunt system for hydrocephalus treatment

Looking Ahead

J&J, Medtronic back CereVasc's $85M funding round

Source reference: original announcement/article.